Biotech & MedTech News
-
FendX to Conduct Third Pilot Run on Dunmore’s Commercial Manufacturing Line for Further Development of REPELWRAP(TM) Film
January 24, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”) a nanotechnology…
-
FendX Technologies to Present at The Microcap Conference in Atlantic City, New Jersey
January 23, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”) a nanotechnology…
-
Zentek Completes Study Quantifying Energy and Emission Savings of ZenGUARD(TM)-Enhanced HVAC Filters
January 22, 2024 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company,…
-
Zentek Announces Eric Wallman Appointed as Chairman of the Board
January 19, 2024 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company,…
-
DIAGNOS Appoints New Chief Operating Officer
January 16, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
FendX Technologies to Participate at Upcoming AlphaNorth Capital Event
January 12, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a nanotechnology…
-
FendX Completes Second Pilot Run to Manufacture REPELWRAP(TM) Film Using Dunmore’s Commercial Equipment
January 10, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a nanotechnology…
-
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
January 9, 2024 (Source) — Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences…
-
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
January 4, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing…
-
Hemostemix Clarifies its October 3, 2023 News Release
December 29, 2023 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
